期刊
AMERICAN JOURNAL OF PATHOLOGY
卷 178, 期 2, 页码 911-923出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2010.10.012
关键词
-
类别
资金
- National Science Council [97-2314-B-002-049, 99-2628-B-002-013, 96-2314-B-002-059]
- National Taiwan University Hospital [98N1264]
- Ta-Tung Kidney Foundation
- Mrs. Hsiu-Chin Lee Kidney Research Foundation
- National Institutes of Health [DK73299, DK84077, DK87389, HL074267-01, NS052830-01]
Microvascular pericytes and perivascular fibroblasts have recently been identified as the source of scar-producing myofibroblasts that appear after injury of the kidney. We show that cross talk between pericytes and endothelial cells concomitantly dictates development of fibrosis and loss of microvasculature after injury. When either platelet-derived growth factor receptor (R)-beta signaling in pericytes or vascular endothelial growth factor (VEGF)R2 signaling in endothelial cells was blocked by circulating soluble receptor ectodomains, both fibrosis and capillary rarefaction were markedly attenuated during progressive kidney injury. Blockade of either receptor-mediated signaling pathway prevented pericyte differentiation and proliferation, but VEGFR2 blockade also attenuated recruitment of inflammatory macrophages throughout disease progression. Whereas Injury down-regulated angiogenic VEGF164, the dys-angiogenic isomers VEGF120 and VEGF188 were up-regulated, suggesting that pericyte-myofibroblast differentiation triggers endothelial loss by a switch in secretion of VEGF isomers. These findings link fibrogenesis inextricably with microvascular rarefaction for the first time, add new significance to fibrogenesis, and identify novel therapeutic targets. (Am J Pathol 2011, 178:911-923; DOI: 10.1016/j.ajpath.2010.10.012)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据